OBJECTIVES: To determine whether bcl-2, a protein that inhibits apoptosis, would be increased in cerebrospinal fluid (CSF) in infants and children after traumatic brain injury (TBI) and to examine the association of bcl-2 concentration with clinical variables. STUDY DESIGN: Bcl-2 was measured in CSF from 23 children (aged 2 months-16 years) with severe TBI and from 19 children without TBI or meningitis (control subjects) by enzyme-linked immunosorbent assay. CSF oligonucleosome concentration was also determined as a marker of DNA degradation. Brain samples from 2 patients undergoing emergent decompressive craniectomies were analyzed for bcl-2 with Western blot and for DNA fragmentation with TUNEL (terminal deoxynucleotidyl-transferase mediated biotin-dUTP nick-end labeling). RESULTS: CSF bcl-2 concentrations were increased in patients with TBI versus control subjects (P =.01). Bcl-2 was increased in patients with TBI who survived versus those who died (P =.02). CSF oligonucleosome concentration tended to be increased after TBI (P =.07) and was not associated with bcl-2. Brain tissue samples showed an increase in bcl-2 in patients with TBI versus adult brain bank control samples and evidence of DNA fragmentation within cells with apoptotic morphology. CONCLUSIONS: Bcl-2 may participate in the regulation of cell death after TBI in infants and children. The increase in bcl-2 seen in patients who survived is consistent with a protective role for this anti-apoptotic protein after TBI.
OBJECTIVES: To determine whether bcl-2, a protein that inhibits apoptosis, would be increased in cerebrospinal fluid (CSF) in infants and children after traumatic brain injury (TBI) and to examine the association of bcl-2 concentration with clinical variables. STUDY DESIGN:Bcl-2 was measured in CSF from 23 children (aged 2 months-16 years) with severe TBI and from 19 children without TBI or meningitis (control subjects) by enzyme-linked immunosorbent assay. CSF oligonucleosome concentration was also determined as a marker of DNA degradation. Brain samples from 2 patients undergoing emergent decompressive craniectomies were analyzed for bcl-2 with Western blot and for DNA fragmentation with TUNEL (terminal deoxynucleotidyl-transferase mediated biotin-dUTP nick-end labeling). RESULTS: CSF bcl-2 concentrations were increased in patients with TBI versus control subjects (P =.01). Bcl-2 was increased in patients with TBI who survived versus those who died (P =.02). CSF oligonucleosome concentration tended to be increased after TBI (P =.07) and was not associated with bcl-2. Brain tissue samples showed an increase in bcl-2 in patients with TBI versus adult brain bank control samples and evidence of DNA fragmentation within cells with apoptotic morphology. CONCLUSIONS:Bcl-2 may participate in the regulation of cell death after TBI in infants and children. The increase in bcl-2 seen in patients who survived is consistent with a protective role for this anti-apoptotic protein after TBI.
Authors: Stefania Mondello; Uwe Muller; Andreas Jeromin; Jackson Streeter; Ronald L Hayes; Kevin K W Wang Journal: Expert Rev Mol Diagn Date: 2011-01 Impact factor: 5.225
Authors: Nicole Zangrilli Hoh; Amy K Wagner; Sheila A Alexander; Robert B Clark; Sue R Beers; David O Okonkwo; Dianxu Ren; Yvette P Conley Journal: J Neurotrauma Date: 2010-08 Impact factor: 5.269
Authors: Amy K Wagner; Krutika B Amin; Christian Niyonkuru; Brett A Postal; Emily H McCullough; Haishin Ozawa; C Edward Dixon; Hulya Bayir; Robert S Clark; Patrick M Kochanek; Anthony Fabio Journal: J Cereb Blood Flow Metab Date: 2011-03-30 Impact factor: 6.200
Authors: Akiko Iwata; Vicki Morgan-Stevenson; Barbara Schwartz; Li Liu; Joan Tupper; Xiaodong Zhu; John Harlan; Robert Winn Journal: PLoS One Date: 2010-02-08 Impact factor: 3.240
Authors: Roya Tehranian; Marie E Rose; Vincent Vagni; Alicia M Pickrell; Raymond P Griffith; Hao Liu; Robert S B Clark; C Edward Dixon; Patrick M Kochanek; Steven H Graham Journal: J Neurotrauma Date: 2008-07 Impact factor: 5.269
Authors: Ericka L Fink; Yichen Lai; Xiaopeng Zhang; Keri Janesko-Feldman; P David Adelson; Csaba Szabó; Rachel P Berger; Ajit A Sarnaik; Patrick M Kochanek; Robert S B Clark Journal: J Cereb Blood Flow Metab Date: 2008-05-28 Impact factor: 6.200